Phase 2 Study of PEG-Intron in Hereditary Hemorrhagic Telangiectasia
Status:
Terminated
Trial end date:
2011-09-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to evaluate the safety and tolerability of pegylated interferon
alpha-2b (PEG-Intron) in patients with severe complications related to Hereditary hemorrhagic
telangiectasia (HHT).
Funding Source - FDA Office of Orphan Products Development (OOPD)
Phase:
Phase 2
Details
Lead Sponsor:
Mayo Clinic
Collaborators:
Augusta University Schering-Plough St. Michael's Hospital, Toronto Unity Health Toronto